Biotech Startups

Valion Bio (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod, a TLR5 agonist that activates the innate immune system, for Acute Radiation Syndrome and oncology supportive care such as chemotherapy- and radiation-induced neutropenia. It also owns Velocity Bioworks, a U.S.-based contract development and manufacturing organization (CDMO) in San Antonio, Texas.

5 investors

5 investors

TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation. The company runs clinical studies across Europe and the US targeting structural heart institutions and cardiac patients.

5 investors

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases. The biotech company focuses on targeting the underlying biology of disease to change the standard of care for patients.

5 investors

5 investors

Upstream Biotechnology develops RNA-based seed traits that regulate crop immune defenses at the gene-expression level, activating disease and stress responses only in the affected tissue to limit yield drag. Its SwitchBlade platform targets crops such as corn, soybean, canola, and rice and is developed in collaboration with seed and crop technology companies.

5 investors

Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration. The company leverages its interchangeable platform to engineer medicines with extended therapeutic durability and improved potency for vision-threatening conditions.

5 investors

Varinos develops and provides genetic testing services applying genome technology, including a uterine microbiome (endometrial flora) test used in fertility and reproductive medicine. The company serves patients and clinics addressing infertility.

5 investors

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery. The company has advanced lead programs in Parkinson's disease and lupus through Phase 2 clinical trials.

5 investors

Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.

5 investors

Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.

5 investors

VIDA provides AI-powered imaging biomarkers and clinical trial imaging services for life-sciences sponsors, built on its VIDA Intelligence Platform to collect and analyze imaging data across drug development and trials. Its quantitative imaging covers respiratory, cardiovascular, oncology, neurology, musculoskeletal, and gastroenterology therapeutic areas, along with digital biobank capabilities.

5 investors

ViewsML applies AI to support the development and delivery of precision medicines, including virtual IHC technology for pathology. It operates in the AI-driven healthcare and diagnostics space.

5 investors

Vincere develops therapeutics for age-related diseases such as Parkinson's and kidney disease, using a computational platform that combines human genetics, cellular network models, and in-silico biology to identify drug targets like USP30 for mitochondrial repair. The company is developing small-molecule candidates aimed at human trials and pharma partnerships.

5 investors

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.

5 investors

Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies. Its team spans drug discovery, clinical development, and business strategy to bring new oncology treatments to patients.

5 investors

Wild Microbes uses synthetic biology to engineer microbes sourced from diverse wild biomes into production hosts for biomanufacturing high-performance ingredients. Its product pipeline spans emulsifiers, cleansers, vitamins, supplements, and industrial chemicals for partners seeking renewable, microbe-made inputs.

5 investors

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases. Its lead program WIN378 is an ultra long-acting anti-TSLP antibody in a Phase 2/3 asthma trial and Phase 2 COPD study, with a broader pipeline including the anti-TSLPxIL-13 bispecific WIN027.

5 investors

Yoneda Labs applies AI/ML and high-throughput experimentation (HTE) to chemical reaction optimization, including cross-coupling reactions, for the life sciences and pharmaceutical research market. The company combines chemistry research, software, and robotics to optimize synthetic reactions.

5 investors

YourChoice Therapeutics develops YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials that works by blocking a receptor essential for sperm production. The company targets men seeking an alternative to condoms or vasectomy.

5 investors

Zya develops naturally-derived enzymes that change how the body processes food after eating, aiming to improve nutrition without altering taste. Its technology is offered to food brands as an ingredient in the food technology and nutrition space.

5 investors

Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D. It operates as a royalty-driven organization that builds and manages a portfolio of healthcare assets through partnerships and collaborations across multiple therapeutic areas.

5 investors

ZymVol uses a physics-AI computational approach combining bioinformatics, molecular modelling, and AI to model enzyme function and predict biocatalyst performance in silico. It serves R&D teams across industries to accelerate enzyme engineering and biocatalysis campaigns by prioritizing top-performing candidates before lab work.

5 investors

Optieum develops next-generation CAR-T cell therapies using a proprietary CAR discovery platform to optimize immune cell activation for treating solid tumors and hematological malignancies. The company engineers precision CAR constructs to enhance T-cell therapeutic efficacy.

5 investors